{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:31:32Z","timestamp":1773268292032,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T00:00:00Z","timestamp":1547856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s12020-018-01836-2","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T12:39:55Z","timestamp":1547901595000},"page":"545-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells"],"prefix":"10.1007","volume":"63","author":[{"given":"Valentina","family":"Maggisano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Celano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio Massimo","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Sponziello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rosignolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Pecce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Verrienti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Baldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catia","family":"Mio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Allegri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Maranghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Damante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-1595","authenticated-orcid":false,"given":"Diego","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bulotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,19]]},"reference":[{"key":"1836_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nrendo.2016.110","volume":"12","author":"CM Kitahara","year":"2016","unstructured":"C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12, 646\u2013653 (2016)","journal-title":"Nat. Rev. Endocrinol."},{"key":"1836_CR2","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388, 2783\u20132795 (2016)","journal-title":"Lancet"},{"key":"1836_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s12020-015-0830-4","volume":"52","author":"S Bulotta","year":"2016","unstructured":"S. Bulotta, M. Celano, G. Costante, D. Russo, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 52, 214\u2013221 (2016)","journal-title":"Endocrine"},{"key":"1836_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.03.012","volume":"125","author":"Y Jin","year":"2018","unstructured":"Y. Jin, D. van Nostrand, L. Cheng, M. Liu, L. Chen, Radioiodine refractory differentiated thyroid cancer. Crit. Rev. Oncol. Hematol. 125, 111\u2013120 (2018)","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1836_CR5","doi-asserted-by":"publisher","first-page":"R215","DOI":"10.1530\/EJE-14-0788","volume":"172","author":"EN Klein Hesselink","year":"2015","unstructured":"E.N. Klein Hesselink, D. Steenvoorden, E. Kapiteijn, E.P. Corssmit, A.N. van der Horst-Schrivers, J.D. Lefrandt, T.P. Links, O.M. Dekkers, Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R215\u2013R225 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"1836_CR6","first-page":"1167","volume":"9","author":"W Yimaer","year":"2016","unstructured":"W. Yimaer, A. Abudouyimu, Y. Tian, S. Magaoweiya, D. Bagedati, H. Wen, Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther. 9, 1167\u20131173 (2016)","journal-title":"Onco Targets Ther."},{"issue":"1","key":"1836_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","volume":"25","author":"R Le\u00e3o","year":"2018","unstructured":"R. Le\u00e3o, J.D. Apol\u00f3nio, D. Lee, A. Figueiredo, U. Tabori, P. Castelo-Branco, Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J. Biomed. Sci. 25(1), 22 (2018)","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"1836_CR8","doi-asserted-by":"publisher","first-page":"R129","DOI":"10.1530\/JME-16-0195","volume":"58","author":"A Pestana","year":"2017","unstructured":"A. Pestana, J. Vinagre, M. Sobrinho-Sim\u00f5es, P. Soares, TERT biology and function in cancer: beyond immortalisation. J. Mol. Endocrinol. 58(2), R129\u2013R146 (2017)","journal-title":"J. Mol. Endocrinol."},{"key":"1836_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12672-016-0256-3","volume":"7","author":"A Alzahrani","year":"2016","unstructured":"A. Alzahrani, R. Alsaadi, A.K. Murugan, B.B. Sadiq, TERT promoter mutations in thyroid cancer. Horm. Cancer 7, 165\u2013177 (2016)","journal-title":"Horm. Cancer"},{"key":"1836_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"X Liu","year":"2013","unstructured":"X. Liu, J. Bishop, Y. Shan, S. Pai, D. Liu, A.K. Murugan, H. Sun, A.K. El-Naggar, M. Xing, Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr. Rel. Cancer 20, 603\u2013610 (2013)","journal-title":"Endocr. Rel. Cancer"},{"key":"1836_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","volume":"27","author":"B Xu","year":"2016","unstructured":"B. Xu, R. Ghossein, Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr. Pathol. 27, 205\u2013212 (2016)","journal-title":"Endocr. Pathol."},{"key":"1836_CR12","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"R. Liu, M. Xing, TERT promoter mutations in thyroid cancer. Endocr. Rel. Cancer 23, R143\u2013R155 (2016)","journal-title":"Endocr. Rel. Cancer"},{"issue":"10","key":"1836_CR13","doi-asserted-by":"publisher","first-page":"101042831771391","DOI":"10.1177\/1010428317713913","volume":"39","author":"HG Vuong","year":"2017","unstructured":"H.G. Vuong, A.M. Altibi, U.N. Duong, H.T. Ngo, T.Q. Pham, H.M. Tran, N. Oishi, K. Mochizuki, T. Nakazawa, L. Hassell, R. Katoh, T. Kondo, Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: promising value of TERT promoter mutations and insignificant role of BRAF mutations\u2014a meta-analysis. Tumour Biol. 39(10), 1010428317713913 (2017)","journal-title":"Tumour Biol."},{"issue":"3","key":"1836_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12020-018-1642-0","volume":"61","author":"GC Penna","year":"2018","unstructured":"G.C. Penna, A. Pestana, J.M. Cameselle, D. Momesso, F.A. de Andrade, A.P.A. Vidal, M.L. Araujo Junior, M. Melo, P.V. Fernandes, R. Corbo, M. Vaisman, M. Sobrinho-Sim\u00f5es, P. Soares et al. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma. Endocrine 61(3), 489\u2013498 (2018)","journal-title":"Endocrine"},{"key":"1836_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.mce.2014.10.019","volume":"399","author":"M Muzza","year":"2015","unstructured":"M. Muzza, C. Colombo, S. Rossi, D. Tosi, V. Cirello, M. Perrino, S. De Leo, E. Magnani, E. Pignatti, B. Vigo, M. Simoni, G. Bulfamante, L. Vicentini et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol. Cell. Endocrinol. 399, 288\u2013295 (2015)","journal-title":"Mol. Cell. Endocrinol."},{"key":"1836_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mce.2017.03.007","volume":"448","author":"V Maggisano","year":"2017","unstructured":"V. Maggisano, M. Celano, S. Lepore, G.E. Lombardo, M. Sponziello, F. Rosignolo, A. Verrienti, F. Baldan, E. Puxeddu, C. Durante, S. Filetti, G. Damante, D. Russo et al. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol. Cell. Endocrinol. 448, 34\u201340 (2017)","journal-title":"Mol. Cell. Endocrinol."},{"key":"1836_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1096\/fj.201601111R","volume":"31","author":"D Cheng","year":"2017","unstructured":"D. Cheng, Y. Zhao, S. Wang, F. Zhang, M. Russo, S.B. McMahon, J. Zhu, Repression of telomerase gene promoter requires human-specific genomic context and is mediated by multiple HDAC1-containing corepressor complexes. FASEB J. 31, 1165\u20131178 (2017)","journal-title":"FASEB J."},{"key":"1836_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mce.2017.05.036","volume":"469","author":"M Celano","year":"2018","unstructured":"M. Celano, C. Mio, M. Sponziello, A. Verrienti, S. Bulotta, C. Durante, G. Damante, D. Russo, Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. Mol. Cell. Endocrinol. 469, 38\u201347 (2018)","journal-title":"Mol. Cell. Endocrinol."},{"key":"1836_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3803\/EnM.2017.32.3.326","volume":"32","author":"X Zhu","year":"2017","unstructured":"X. Zhu, S.Y. Cheng, Epigenetic modifications: novel therapeutic approach for thyroid cancer. Endocrinol. Metab. 32, 326\u2013331 (2017)","journal-title":"Endocrinol. Metab."},{"issue":"4","key":"1836_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1530\/ERC-15-0322","volume":"23","author":"C Mio","year":"2016","unstructured":"C. Mio, E. Lavarone, F. Baldan, B. Toffoletto, C. Puppin, S. Filetti, C. Durante, D. Russo, A. Orlacchio, A. Di Cristofano, C. Di Loreto, G. Damante, MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr. Relat. Cancer 23(4), 335\u2013347 (2016)","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"1836_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2015.12.008","volume":"469","author":"X Gao","year":"2016","unstructured":"X. Gao, X. Wu, X. Zhang, W. Hua, Y. Zhang, Y. Maimaiti, Z. Gao, Y. Zhang, Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochem. Biophys. Res. Commun. 469(3), 679\u2013685 (2016)","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"1836_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","volume":"12","author":"M P\u00e9rez-Salvia","year":"2017","unstructured":"M. P\u00e9rez-Salvia, M. Esteller, Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics 12(5), 323\u2013339 (2017)","journal-title":"Epigenetics"},{"issue":"5","key":"1836_CR23","volume":"8","author":"E Wadhwa","year":"2016","unstructured":"E. Wadhwa, T. Nicolaides, Bromodomain inhibitor review: bromodomain and extra-terminal family protein inhibitors as a potential new therapy in central nervous system tumors. Cureus 8(5), e620 (2016)","journal-title":"Cureus"},{"key":"1836_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1089\/oli.2004.14.263","volume":"14","author":"S Natarajan","year":"2004","unstructured":"S. Natarajan, Z. Chen, E.V. Wancewicz, B.P. Monia, D.R. Corey, Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides 14, 263\u2013273 (2004)","journal-title":"Oligonucleotides"},{"key":"1836_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3892\/ijo.2013.2051","volume":"43","author":"W Zhang","year":"2013","unstructured":"W. Zhang, L. Xing, RNAi gene therapy of SiHa cells via targeting human TERT induces growth inhibition and enhances radiosensitivity. Int. J. Oncol. 43, 1228\u20131234 (2013)","journal-title":"Int. J. Oncol."},{"key":"1836_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107019","volume":"9","author":"AQ Liu","year":"2014","unstructured":"A.Q. Liu, L.Y. Ge, X. Lu, X.L. Luo, Y. Cai, X.Q. Ye, F.F. Geng, Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo. PLoS ONE 9, e107019 2014).","journal-title":"PLoS ONE"},{"key":"1836_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/cgt.2017.22","volume":"24","author":"P Chen","year":"2017","unstructured":"P. Chen, W.L. Gu, M.Z. Gong, J. Wang, D.Q. Li, shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells. Cancer Gene Ther. 24, 325\u2013332 (2017)","journal-title":"Cancer Gene Ther."},{"key":"1836_CR28","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1210\/jc.2002-021222","volume":"88","author":"L Teng","year":"2003","unstructured":"L. Teng, M.C. Specht, C.B. Barden, T.J.Fahey III, Antisense hTERT inhibits thyroid cancer cell growth. J. Clin. Endocrinol. Metab. 88, 1362\u20131366 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"1836_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1158\/1535-7163.MCT-17-0559","volume":"17","author":"GE Lombardo","year":"2018","unstructured":"G.E. Lombardo, V. Maggisano, M. Celano, D. Cosco, C. Mignogna, F. Baldan, S.M. Lepore, L. Allegri, S. Moretti, C. Durante, G. Damante, M. Fresta, D. Russo et al. Anti-hTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. Mol. Cancer Ther. 17(6), 1187\u20131195 (2018)","journal-title":"Mol. Cancer Ther."},{"key":"1836_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1\u2013133 (2016)","journal-title":"Thyroid"},{"key":"1836_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12020-017-1240-6","volume":"59","author":"M Celano","year":"2018","unstructured":"M. Celano, C. Mignogna, F. Rosignolo, M. Sponziello, M. Iannone, S.M. Lepore, G.E. Lombardo, V. Maggisano, A. Verrienti, S. Bulotta, C. Durante, C. Di Loreto, G. Damante et al. Expression of YAP1 in aggressive thyroid cancer. Endocrine 59, 209\u2013212 (2018)","journal-title":"Endocrine"},{"key":"1836_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.mce.2016.05.007","volume":"431","author":"M Sponziello","year":"2016","unstructured":"M. Sponziello, F. Rosignolo, M. Celano, V. Maggisano, V. Pecce, R.F. De Rose, G.E. Lombardo, C. Durante, S. Filetti, G. Damante, D. Russo, S. Bulotta, Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. Mol. Cell. Endocrinol. 431, 123\u2013132 (2016)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"1836_CR33","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1210\/jc.2008-1102","volume":"93","author":"RE Schweppe","year":"2008","unstructured":"R.E. Schweppe, J.P. Klopper, C. Korch, U. Puqazhenthi, M. Benezra, J.A. Knauf, J.A. Fagin, L.A. Marlow, J.A. Copland, R.C. Smallridge, B.R. Haugen, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93(11), 4331\u20134341 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1836_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3803\/EnM.2016.31.1.100","volume":"31","author":"MJ Jeon","year":"2016","unstructured":"M.J. Jeon, W.G. Kim, S. Sim, S. Lim, H. Kwon, T.Y. Kim, Y.K. Shong, W.B. Kim, Low prevalence of somatic TERT promoter mutations in classic papillary thyroid carcinoma. Endocrinol. Metab. 31, 100\u2013104 (2016)","journal-title":"Endocrinol. Metab."},{"key":"1836_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1530\/JME-13-0160","volume":"52","author":"M D\u2019Agostino","year":"2014","unstructured":"M. D\u2019Agostino, M. Sponziello, C. Puppin, M. Celano, V. Maggisano, F. Baldan, M. Biffoni, S. Bulotta, C. Durante, S. Filetti, G. Damante, D. Russo, Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J. Mol. Endocrinol. 52, 121\u2013131 (2014)","journal-title":"J. Mol. Endocrinol."},{"issue":"7","key":"1836_CR36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/01635581.2015.1073760","volume":"67","author":"M Celano","year":"2015","unstructured":"M. Celano, V. Maggisano, R.F. De Rose, S. Bulotta, J. Maiuolo, M. Navarra, D. Russo, Flavonoid fraction of Citrus reticulata juice reduces proliferation and migration of anaplastic thyroid carcinoma cells. Nutr. Cancer 67(7), 1183\u20131190 (2015)","journal-title":"Nutr. Cancer"},{"issue":"11","key":"1836_CR37","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/2159-8290.CD-16-0177","volume":"6","author":"SC Ak\u0131nc\u0131lar","year":"2016","unstructured":"S.C. Ak\u0131nc\u0131lar, E. Khattar, P.L. Boon, B. Unal, M.J. Fullwood, V. Tergaonkar, Long-range chromatin interactions drive mutant TERT promoter activation. Cancer Discov. 6(11), 1276\u20131291 (2016)","journal-title":"Cancer Discov."},{"key":"1836_CR38","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1530\/ERC-17-0542","volume":"25","author":"A Berdelou","year":"2018","unstructured":"A. Berdelou, L. Lamartina, M. Klain, S. Leboulleux, M. Schlumberger, Treatment of refractory thyroid cancer. Endocr. Rel. Cancer 25, R209\u2013R223 (2018)","journal-title":"Endocr. Rel. Cancer"},{"key":"1836_CR39","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"J.A. Fagin, S.A. Wells Jr., Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375, 1054\u20131067 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1836_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-pathol-121808-102139","volume":"13","author":"TJ Giordano","year":"2018","unstructured":"T.J. Giordano, Genomic hallmarks of thyroid neoplasia. Annu. Rev. Pathol. 13, 141\u2013162 (2018)","journal-title":"Annu. Rev. Pathol."},{"issue":"2","key":"1836_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12020-017-1499-7","volume":"59","author":"M Molina-Vega","year":"2018","unstructured":"M. Molina-Vega, J. Garc\u00eda-Alem\u00e1n, A. Sebasti\u00e1n-Ochoa, I. Mancha-Doblas, M. Trigo-P\u00e9rez, F. Tinahones-Madue\u00f1o, Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine 59(2), 395\u2013401 (2018)","journal-title":"Endocrine"},{"issue":"9","key":"1836_CR42","doi-asserted-by":"publisher","first-page":"E2647","DOI":"10.3390\/ijms19092647","volume":"19","author":"D Rusinek","year":"2018","unstructured":"D. Rusinek, A. Pfeifer, J. Krajewska, M. Oczko-Wojciechowska, D. Handkiewicz-Junak, A. Pawlaczek, J. Zebracka-Gala, M. Kowalska, R. Cyplinska, E. Zembala-Nozynska, M. Chekan, E. Chmielik, A. Kropinska et al. Coexistence of TERT promoter mutations and the BRAF V600E alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of Polish patients. Int. J. Mol. Sci. 19(9), E2647 (2018)","journal-title":"Int. J. Mol. Sci."},{"key":"1836_CR43","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","volume":"32","author":"M Xing","year":"2014","unstructured":"M. Xing, R. Liu, X. Liu, A.K. Murugan, G. Zhu, M.A. Zeiger, S. Pai, J. Bishop, BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 32, 2718\u20132726 (2014)","journal-title":"J. Clin. Oncol."},{"key":"1836_CR44","doi-asserted-by":"crossref","first-page":"18346","DOI":"10.18632\/oncotarget.7811","volume":"7","author":"L Jin","year":"2016","unstructured":"L. Jin, E. Chen, S. Dong, Y. Cai, X. Zhang, Y. Zhou, R. Zeng, F. Yang, C. Pan, Y. Liu, W. Wu, M. Xing, X. Zhang et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 7, 18346\u201318355 (2016)","journal-title":"Oncotarget"},{"issue":"5","key":"1836_CR45","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/thy.2016.0350","volume":"27","author":"S Moon","year":"2017","unstructured":"S. Moon, Y.S. Song, Y.A. Kim, J.A. Lim, S.W. Cho, J.H. Moon, S. Hahn, D.J. Park, Y.J. Park, Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 27(5), 651\u2013660 (2017)","journal-title":"Thyroid"},{"issue":"5","key":"1836_CR46","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4158\/EP171983.OR","volume":"24","author":"Z Kordestani","year":"2018","unstructured":"Z. Kordestani, M. Sanjari, M. Safavi, M. Mashrouteh, G. Asadikaram, M.F.S. Abadi, A. Mirzazadeh, Enhanced beta-catenin expression is associated with recurrence of papillary thyroid carcinoma. Endocr. Pract. 24(5), 411\u2013418 (2018)","journal-title":"Endocr. Pract."},{"key":"1836_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03033-1","volume":"9","author":"X Liu","year":"2018","unstructured":"X. Liu, T. Zhang, G. Zhu, M. Xing, Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nat. Commun. 9, 579 (2018)","journal-title":"Nat. Commun."},{"key":"1836_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2017.07.012","volume":"469","author":"SL Asa","year":"2018","unstructured":"S.L. Asa, S. Ezzat, The epigenetic landscape of differentiated thyroid cancer. Mol. Cell. Endocrinol. 469, 3\u201310 (2018)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"1836_CR49","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"D.B. Doroshow, J.P. Eder, P.M. LoRusso, BET inhibitors: a novel epigenetic approach. Ann. Oncol. 28(8), 1776\u20131787 (2017)","journal-title":"Ann. Oncol."},{"issue":"4","key":"1836_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/1574892812666170808121228","volume":"12","author":"I Ali","year":"2017","unstructured":"I. Ali, G. Choi, K. Lee, BET inhibitors as anticancer agents: a patent review. Recent Pat Anticancer Drug Discov. 12(4), 340\u2013364 (2017)","journal-title":"Recent Pat Anticancer Drug Discov."},{"key":"1836_CR51","first-page":"582","volume":"39","author":"C Mio","year":"2018","unstructured":"C. Mio, K. Conzatti, F. Baldan, L. Allegri, M. Sponziello, F. Rosignolo, D. Russo, S. Filetti, G. Damante, BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells. Oncol. Rep. 39, 582\u2013588 (2018)","journal-title":"Oncol. Rep."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-01836-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-01836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-01836-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T23:53:19Z","timestamp":1606089199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-01836-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,19]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-01836-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,19]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}